Immunome (IMNM) Assets (2019 - 2026)

Immunome has reported Assets for 8 years, with the latest figure at $619.8 million in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 80.86% year-over-year to $619.8 million; the trailing twelve-month figure through Mar 2026 stood at $619.8 million (up 80.86% YoY), and the FY2025 full-year result was $683.2 million, up 184.38% from the prior year.
• Assets for Q1 2026 stood at $619.8 million, down from $683.2 million in the prior quarter.
• The five-year high for Assets was $683.2 million in Q4 2025, with the low at $24.0 million in Q4 2022.
• Historically, Assets has averaged $225.1 million across 5 years, with a median of $240.2 million in 2024.
• Annual changes were most pronounced in 2022 — Assets sank 58.49% — and 2024, when it jumped 614.89%.
• Immunome's Assets stood at $24.0 million in 2022, then jumped by 517.73% to $148.5 million in 2023, then jumped by 61.73% to $240.2 million in 2024, then soared by 184.38% to $683.2 million in 2025, then dropped by 9.28% to $619.8 million in 2026.
• The last three Assets figures came in at $619.8 million (Q1 2026), $683.2 million (Q4 2025), and $299.4 million (Q3 2025), per Business Quant data.